News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-444

Its a patently misleading claim. Because the cost of the procedure itself is not the issue.

It's the comparitive cost of hospitalisation, and post operative care. It's the cost of repeat procedures and complications because of inferior durability. It's the cost of patient's dying. (Oh sorry that's a human cost and not considered by jag142).

THOSE costs are pivotal in informed and integrated purchasing decisions.